| hsa-miR-1269a |
hsa04919 |
Thyroid hormone signaling pathway |
3.60E−04 |
CCND1/FOXO1/SLC16A2 |
| hsa-miR-1269a |
hsa05215 |
Prostate cancer |
6.18E−03 |
CCND1/FOXO1 |
| hsa-miR-1269a |
hsa04933 |
AGE-RAGE signaling pathway in diabetic complications |
6.56E−03 |
CCND1/FOXO1 |
| hsa-miR-1269a |
hsa05165 |
Human papillomavirus infection |
6.78E−034 |
CCND1/FOXO1/PTGER4 |
| hsa-miR-1269a |
hsa04152 |
AMPK signaling pathway |
9.33E−03 |
CCND1/FOXO1 |
| hsa-miR-1269a |
hsa04068 |
FoxO signaling pathway |
3.60E−02 |
CCND1/FOXO1 |
| hsa-miR-1269a |
hsa04371 |
Apelin signaling pathway |
1.20E−02 |
CCND1/MEF2D |
| hsa-miR-1269a |
hsa04218 |
Cellular senescence |
1.62E−02 |
CCND1/FOXO1 |
| hsa-miR-1269a |
hsa00120 |
Primary bile acid biosynthesis |
2.11E−02 |
CYP7B1 |
| hsa-miR-1269a |
hsa05163 |
Human cytomegalovirus infection |
3.07E−02 |
CCND1/PTGER4 |
| hsa-miR-1269a |
hsa05216 |
Thyroid cancer |
4.54E−02 |
CCND1 |
| hsa-miR-147b |
hsa03015 |
mRNA surveillance pathway |
4.49E−02 |
WDR82 |
| hsa-miR-224-5p |
hsa04310 |
Wnt signaling pathway |
1.28E−03 |
CAMK2D/GSK3B/LRP6/ MAP3K7/FZD4 |
| hsa-miR-31-3p |
hsa05033 |
Nicotine addiction |
1.00E−02 |
GRIN2A |
| hsa-miR-31-3p |
hsa05030 |
Cocaine addiction |
1.22E−02 |
GRIN2A |
| hsa-miR-31-3p |
hsa05014 |
Amyotrophic lateral sclerosis (ALS) |
1.42E−02 |
GRIN2A |
| hsa-miR-31-3p |
hsa04720 |
Long-term potentiation |
1.67E−02 |
GRIN2A |
| hsa-miR-31-3p |
hsa05031 |
Amphetamine addiction |
1.72E−02 |
GRIN2A |
| hsa-miR-31-3p |
hsa05211 |
Renal cell carcinoma |
1.72E−02 |
ELOC |
| hsa-miR-31-3p |
hsa04713 |
Circadian entrainment |
2.42E−02 |
GRIN2A |
| hsa-miR-31-3p |
hsa05017 |
Spinocerebellar ataxia |
2.44E−02 |
GRIN2A |
| hsa-miR-31-3p |
hsa04066 |
HIF-1 signaling pathway |
2.71E−02 |
ELOC |
| hsa-miR-31-3p |
hsa04724 |
Glutamatergic synapse |
2.84E−02 |
GRIN2A |
| hsa-miR-31-3p |
hsa04728 |
Dopaminergic synapse |
3.26E−02 |
GRIN2A |
| hsa-miR-31-3p |
hsa05322 |
Systemic lupus erythematosus |
3.30E−02 |
GRIN2A |
| hsa-miR-31-3p |
hsa04120 |
Ubiquitin mediated proteolysis |
3.38E−02 |
ELOC |
| hsa-miR-31-3p |
hsa05010 |
Alzheimer disease |
4.24E−02 |
GRIN2A |
| hsa-miR-31-3p |
hsa05034 |
Alcoholism |
4.56E−02 |
GRIN2A |
| hsa-miR-31-3p |
hsa04020 |
Calcium signaling pathway |
4.78E−02 |
GRIN2A |
| hsa-miR-31-5p |
hsa04360 |
Axon guidance |
9.68E−04 |
FZD3/CAMK2D/PLXNA2/ PPP3CA/RASA1/PLXNA4 |
| hsa-miR-371a-3p |
hsa00513 |
Various types of N-glycan biosynthesis |
1.94E−02 |
MAN2A2 |
| hsa-miR-371a-3p |
hsa00510 |
N-Glycan biosynthesis |
2.48E−02 |
MAN2A2 |
| hsa-miR-371a-3p |
hsa03015 |
mRNA surveillance pathway |
4.49E−02 |
DAZAP1 |
